Charles Swindell | Liver Disease Diagnostics and Glycoprotein Biomarkers
Charles Swindell joins Executive Insights for Life Sciences Innovators to discuss diagnostic innovation, liver disease detection, and the development of biomarker technologies designed to improve clinical decision-making.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Charles Swindell discusses how Glycotest is leveraging proprietary technology that measures glycoprotein fucosylation to improve the detection of liver diseases. The conversation explores biomarker development, diagnostic innovation, and the opportunities and challenges involved in bringing advanced diagnostic technologies into clinical practice.
Key Themes
- Liver disease diagnostics and early detection
- Glycoprotein fucosylation as a biomarker
- Diagnostic innovation in healthcare
- Translating scientific discoveries into clinical tools
- Biomarker development and commercialization
- Improving clinical decision-making through advanced diagnostics
Why This Matters for Life Sciences Leaders
As healthcare continues to shift toward earlier detection and more personalized care, innovative diagnostic technologies are becoming increasingly important. The conversation highlights how biomarker-driven approaches can improve disease identification and patient management, while also underscoring the scientific, regulatory, and commercial considerations involved in building successful diagnostics companies.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
